Subtopic Deep Dive
Papillary Thyroid Carcinoma Genomics
Research Guide
What is Papillary Thyroid Carcinoma Genomics?
Papillary Thyroid Carcinoma Genomics examines BRAF, RAS, and RET/PTC mutations alongside gene expression profiles in papillary thyroid cancer to correlate genomic alterations with clinical behavior and targeted therapies.
This subtopic centers on the T1799A BRAF V600E mutation, present in 40-60% of PTC cases, which predicts aggressive features like lymph node metastasis (Xing et al., 2005; 984 citations). RET/PTC rearrangements occur in 10-30% of cases, particularly radiation-exposed tumors, influencing clinico-pathological outcomes (Romei and Elisei, 2012; 167 citations). Over 20 studies since 2005 establish genomic testing's role in preoperative risk stratification via fine-needle aspiration biopsy (Xing et al., 2009; 254 citations).
Why It Matters
BRAF mutation testing in fine-needle aspiration biopsy enables preoperative risk stratification, guiding surgical extent and reducing overtreatment in low-risk PTC (Xing et al., 2009). Genomic profiling identifies candidates for targeted therapies like BRAF inhibitors, improving outcomes in advanced cases (Xing, 2007). RET/PTC detection correlates with specific histological variants, informing pediatric management protocols (Lebbink et al., 2022). These applications personalize treatment, with BRAF status influencing decisions on total thyroidectomy versus lobectomy (Yip et al., 2009).
Key Research Challenges
Heterogeneity of BRAF Effects
BRAF V600E drives proliferation and tumorigenicity but its prognostic impact varies by growth pattern and invasiveness (Xing et al., 2005; Eloy et al., 2011). Studies show limited influence on lymph node metastasis independent of histological features (Eloy et al., 2011; 51 citations). Reconciling these discrepancies requires integrated multi-omics analysis.
RET/PTC Detection Sensitivity
RET/PTC translocations show variable prevalence across PTC subtypes, complicating routine screening (Romei and Elisei, 2012). Low sensitivity in fine-needle aspirates hinders preoperative identification (Romei and Elisei, 2012; 167 citations). Advanced molecular techniques are needed for reliable detection.
Translating Genomics to Therapy
Despite BRAF's prevalence, targeted inhibitors face resistance in progressive PTC (Woyach and Shah, 2009). Pediatric guidelines highlight unique molecular profiles requiring tailored approaches (Lebbink et al., 2022; 149 citations). Bridging genomic data to clinical trials remains underdeveloped.
Essential Papers
BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer
Mingzhao Xing, William H. Westra, Ralph P. Tufano et al. · 2005 · The Journal of Clinical Endocrinology & Metabolism · 984 citations
Context: Use of BRAF mutation in papillary thyroid cancer (PTC) has the potential to improve risk stratification of this cancer. Objective: The objective of the study was to investigate the prognos...
BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications
Mingzhao Xing · 2007 · Endocrine Reviews · 980 citations
In recent years, the T1799A B-type Raf kinase (BRAF) mutation in thyroid cancer has received enthusiastic investigation, and significant progress has been made toward understanding its tumorigenic ...
<i>BRAF</i> Mutation Testing of Thyroid Fine-Needle Aspiration Biopsy Specimens for Preoperative Risk Stratification in Papillary Thyroid Cancer
Mingzhao Xing, Douglas P. Clark, Haixia Guan et al. · 2009 · Journal of Clinical Oncology · 254 citations
Purpose This study investigated the utility of BRAF mutation testing of thyroid fine-needle aspiration biopsy (FNAB) specimens for preoperative risk stratification in papillary thyroid cancer (PTC)...
Prognostic utility of BRAF mutation in papillary thyroid cancer
Mingzhao Xing · 2009 · Molecular and Cellular Endocrinology · 211 citations
RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma
Cristina Romei, Rossella Elisei · 2012 · Frontiers in Endocrinology · 167 citations
Thyroid carcinoma is the most frequent endocrine cancer accounting for 5-10% of thyroid nodules. Papillary histotype (PTC) is the most prevalent form accounting for 80% of all thyroid carcinoma. Al...
Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation
Linwah Yip, Marina N. Nikiforova, Sally E. Carty et al. · 2009 · Surgery · 164 citations
2022 European Thyroid Association Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma
Chantal A Lebbink, Thera P. Links, Agnieszka Czarniecka et al. · 2022 · European Thyroid Journal · 149 citations
At present, no European recommendations for the management of pediatric thyroid nodules and differentiated thyroid carcinoma (DTC) exist. Differences in clinical, molecular, and pathological charac...
Reading Guide
Foundational Papers
Start with Xing et al. (2005; 984 citations) for BRAF-prognosis link and Xing (2007; 980 citations) for pathogenic mechanisms; follow with Xing et al. (2009; 254 citations) on FNAB testing and Romei and Elisei (2012; 167 citations) for RET/PTC.
Recent Advances
Lebbink et al. (2022; 149 citations) for pediatric guidelines integrating genomics; Eloy et al. (2011; 51 citations) challenging BRAF-metastasis causality.
Core Methods
PCR/sequencing for BRAF V600E in aspirates (Xing et al., 2009); RT-PCR/FISH for RET/PTC (Romei and Elisei, 2012); expression profiling for pathway analysis (Liu et al., 2007).
How PapersFlow Helps You Research Papillary Thyroid Carcinoma Genomics
Discover & Search
Research Agent uses searchPapers('BRAF V600E papillary thyroid cancer prognosis') to retrieve Xing et al. (2005; 984 citations), then citationGraph to map 200+ citing works on prognostic utility, and findSimilarPapers to uncover RET/PTC studies like Romei and Elisei (2012). exaSearch surfaces pediatric applications from Lebbink et al. (2022).
Analyze & Verify
Analysis Agent applies readPaperContent on Xing et al. (2009) to extract BRAF FNAB mutation rates (45%), verifies claims via verifyResponse (CoVe) against 250M+ OpenAlex papers, and uses runPythonAnalysis for survival curve meta-analysis with pandas on citation data. GRADE grading scores Xing et al. (2005) as high evidence for prognosis.
Synthesize & Write
Synthesis Agent detects gaps in BRAF resistance literature post-Xing (2007), flags contradictions between Eloy et al. (2011) and Xing et al. (2005) on metastasis. Writing Agent employs latexEditText for manuscript sections, latexSyncCitations to integrate 10 papers, latexCompile for PDF, and exportMermaid for mutation pathway diagrams.
Use Cases
"Run survival analysis on BRAF mutation cohorts from PTC papers"
Research Agent → searchPapers('BRAF PTC survival') → Analysis Agent → runPythonAnalysis(pandas meta-analysis of hazard ratios from Xing 2005/2009) → matplotlib Kaplan-Meier plot output.
"Draft LaTeX review on BRAF testing guidelines for PTC"
Synthesis Agent → gap detection (preop stratification) → Writing Agent → latexEditText(structured sections) → latexSyncCitations(15 papers incl. Xing 2009) → latexCompile → PDF with figures.
"Find code for PTC genomic mutation callers"
Research Agent → paperExtractUrls(Xing 2007) → paperFindGithubRepo(BRAF analysis pipelines) → githubRepoInspect → exportCsv(mutation detection scripts for BRAF/RET).
Automated Workflows
Deep Research workflow scans 50+ BRAF/RET papers via searchPapers → citationGraph → structured report with GRADE scores on prognostic claims (Xing et al., 2005). DeepScan's 7-step chain verifies RET/PTC translocation data (Romei and Elisei, 2012) with CoVe checkpoints and runPythonAnalysis for prevalence stats. Theorizer generates hypotheses linking BRAF invasiveness to pediatric outcomes (Lebbink et al., 2022).
Frequently Asked Questions
What defines Papillary Thyroid Carcinoma Genomics?
It examines BRAF V600E, RAS, and RET/PTC mutations plus gene expression in PTC, correlating them to clinical behavior (Xing, 2007).
What are key methods for genomic analysis?
BRAF mutation testing via PCR on fine-needle aspirates for preoperative stratification; RET/PTC detection by FISH or RT-PCR (Xing et al., 2009; Romei and Elisei, 2012).
What are landmark papers?
Xing et al. (2005; 984 citations) links BRAF to poor prognosis; Xing (2007; 980 citations) details pathogenesis; Romei and Elisei (2012; 167 citations) covers RET/PTC features.
What open problems exist?
Heterogeneous BRAF prognostic effects despite histological confounders (Eloy et al., 2011); limited targeted therapies for mutated PTC (Woyach and Shah, 2009).
Research Thyroid Cancer Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Papillary Thyroid Carcinoma Genomics with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.